Safety analysis of the randomized phase II study of FOLFOXIRI plus cetuximab versus FOLFOXIRI plus bevacizumab as the first-line treatment in metastatic colorectal cancer with RAS wild-type tumors: The DEEPER trial (JACCRO CC-13).

Takanori Watanabe,Akihito Tsuji,Manabu Shiozawa,Hirofumi Ota,Hironaga Satake,Taichi Yabuno,Junichi Hasegawa,Mitsugu Kochi,Dai Manaka,Tamotsu Sagawa,Masahito Kotaka,Yutaro Kubota,Yu Sunakawa,Takashi Sekikawa,Masato Nakamura,Masahiro Takeuchi,Wataru Ichikawa,Masashi Fujii

Safety analysis of the randomized phase II study of FOLFOXIRI plus cetuximab versus FOLFOXIRI plus bevacizumab as the first-line treatment in metastatic colorectal cancer with RAS wild-type tumors: The DEEPER trial (JACCRO CC-13).

2021

Takanori Watanabe
Akihito Tsuji
Manabu Shiozawa
Hirofumi Ota
Hironaga Satake
Taichi Yabuno
Junichi Hasegawa
Mitsugu Kochi
Dai Manaka
Tamotsu Sagawa
Masahito Kotaka
Yutaro Kubota
Yu Sunakawa
Takashi Sekikawa
Masato Nakamura
Masahiro Takeuchi
Wataru Ichikawa
Masashi Fujii

86Background: Triplet regimens, FOLFOXIRI, combined with bevacizumab (bev) or panitumumab have been shown to be superior in terms of early tumor shrinkage (ETS) and depth of response (DpR) compared...

Keywords:

Oncology
Internal medicine
Bevacizumab
Colorectal cancer
Cetuximab
first line treatment
FOLFOXIRI
Phases of clinical research
Wild type
Panitumumab
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations